nach oben

Medical Oncology

Erschienen in:

01.09.2007 | Original Paper

Clinical stage-depending decrease of NK cell activity in multiple myeloma patients

verfasst von: Vladimir Jurisic, Tatjana Srdic, Gordana Konjevic, Olivera Markovic, Milica Colovic

Erschienen in: Medical Oncology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Natural killer cells, as an important subpopulation of cells of the innate immune system have an essential role in defense of the rise and spread of malignancy. These cells have a CD3-CD16 + CD56+ phenotype and they are functionally defined by their ability to lyses tumor cells. We here show that decrease of NK cell activity was significantly associated with advanced clinical stage, increased lactate dehydrogenase (LDH), percentage infiltration of bone marrow with plasma cells, and β-2 microglobulin. The patients with higher NK cell activity at presentation after receiving VAD protocol have better cumulative survival in comparison with those with low NK cell activity.

Lotsova E. Natural killer cells: immunobiology and clinical prospects. Cancer Invest 1991;9:173–84.

Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Review article. Blood 1990;76:2421–51.PubMed

Konjevic G, Jurisic V, Banicević B, Spuzic I. Difference in NK cell activity between patients with non-Hodgkin’s lymphoma and Hodgkin’s disease. Br J Haematol 1999;104:144–51.PubMedCrossRef

Konjevic G, Jurisic V, Spuzic I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 2001;66:255–63.PubMedCrossRef

Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999;162:6658–62.PubMed

Whiteside T, Herberman R. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 1995;7:704–10.PubMedCrossRef

Durie BMG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842–9.PubMedCrossRef

Greipp PR, Kyle RA. Staging, kinetics, and prognosis of multiple myeloma. In: Wiernik P, Canelos G, Ducher J, Kyle R, editors. Neoplastic disease of the blood. New York: Churchill Livingstone; 1996. p. 537–59.

Sulica A, Metes D, Cherman M, Whiteside TL, Herberman RB. Divergent effects of Fcγ RIII A on the functional activities of human natural killer cells in vitro. Eur J Immunol 1996;26:1199–203.PubMedCrossRef

10.

Che S, Huston DP. Natural killer cell suppression of IgM production. Nat Immunol 1994;13:258–63.

11.

Farssanito MA, Silvestris F, Cafforio P, Silvestris N, Dammacco F. IgG M-components in multiple myeloma patients induce a down-regulation of natural killer cell activity. Int J Clin Lab Res 1997;27:48–54.

12.

Costelo RT, Fauriat C, Sivory S, Marcenaro E, Olive D. NK cells: innate immunity against hematological malignancies? Trends Immunol 2004;25:328–33.CrossRef

13.

Jurisic V, Spuzic I, Konjevic G. A comparison of NK cell activity with effects of TNF-α against K-562 cells, determined by LDH release assay. Cancer Lett 1999;138:67–72.PubMedCrossRef

14.

Jurisic V, Konjevic G, Jancic-Nedeljkov R, Sretenovic M, Banicevic B, Colovic M, Spuzic I. The comparison of spontaneous LDH release from cultured PBMC with sera LDH activity in Non-Hodgkin’s lymphoma patients. Med Oncol 2004;21:179–85.PubMedCrossRef

15.

Jurisic V. Estimation of cell membrane alteration after drug treatment by LDH release. Blood 2003;101:2894.PubMedCrossRef

16.

Jurisic V, Colovic M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta-2 microglobulin, and clinical stage in multiple myeloma. Med Oncol 2002;19(3):133–9.PubMedCrossRef

17.

Jurisic V, Bogdnovic G, Kojic V, Jakimov D, Srdic T. Effect of TNF-α on Raji cells at different cellular level estimated by various methods. Ann Hematol 2006;85:86–94.PubMedCrossRef

18.

Jurisic V, Kraguljac N, Konjevic G, Spuzic I. TNF-α induced changes in cell membrane antigen expression on K-562 cells is associated with increased LDH release. Neoplasma 2005;1:25–32.

19.

Jurisic V, Bumbasirevic V, Konjevic G, Djuricic B, Spuzic I. TNF-α induced changes in LDH isotype profile following triggering of apoptosis in PBMC of non-Hodgkin’s lymphoma. Ann Hematol 2004;83:84–91.PubMedCrossRef

20.

Ross ME, Caligiuri MA. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 1997;89:910–8.PubMed

21.

Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multiple transformation process. Blood 1998;91:3–21.PubMed

22.

King MA, Radicchi-Mastroianni MA. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-color flow cytometry. Cytometry 1996;15:121–4.CrossRef

23.

Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 2006;20:732–3.PubMedCrossRef

24.

Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Poliio G, Cosman D, Catalano L, Tassone P, Rotoli B, Venuta S. HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005;105:251–8.PubMedCrossRef

25.

Von Lilienteld-Toal M, Nattermann J, Feldman G, Sievers E, Frank S, Strehl J, Schmidt-Wolf GH. Activated yd T cells express the natural killer cytotoxicity receptor natural killer p44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol 2006;144:528–33.CrossRef

26.

Konjevic G, Jovic V, Jurisic V, Radulovic S, Jelic S, Spuzic I. IL-2 mediated augmentation of NK cell activity and activation antigen expression on NK and T cell subsets in metastatic melanoma patients treated with interferon alpha and DTIC. Clin Exp Metastasis 2003;20:647–55.PubMedCrossRef

Titel: Clinical stage-depending decrease of NK cell activity in multiple myeloma patients
verfasst von: Vladimir Jurisic
Tatjana Srdic
Gordana Konjevic
Olivera Markovic
Milica Colovic
Publikationsdatum: 01.09.2007
Verlag: Humana Press Inc
Erschienen in: Medical Oncology / Ausgabe 3/2007
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-007-0007-y

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Clinical stage-depending decrease of NK cell activity in multiple myeloma patients

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

Liver Embolizations in Oncology. A Review. Part II. Arterial Radioembolizations, Portal Venous Embolizations, Experimental Arterial Embolization Procedures

C-reactive protein as an acute phase protein in cancer patients

Intravenous gammaglobulin-induced chronic renal failure in a patient with multiple myeloma

Letter to Editor

Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie